Trials / Unknown
UnknownNCT03089138
Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome
Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase 2b Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Beijing Da-an Bio-technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and Safety of Regan Tangjiang for treating the common cold with wind-heat syndrome: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase 2b Study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regan Tangjiang | The treatment duration is 3 consecutive days. |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2017-03-24
- Last updated
- 2017-03-24
Source: ClinicalTrials.gov record NCT03089138. Inclusion in this directory is not an endorsement.